The Use of Antidepressant Drugs in the Elderly Patient

  • Arthur J. PrangeJr.
Part of the Advances in Behavioral Biology book series (ABBI, volume 6)


Depression is a common syndrome in the general population, and the elderly are not spared. Silverman (1), in her work on the epidemiology of this condition, wrote: “. . . depression . . . reaches it greatest frequency in the middle years, and may decline somewhat in the later years of life.” Even the slight decline, I think, may be more apparent than real because of misdiagnosis. In any case, Roth (2) found that about half the elderly patients admitted to a mental hospital suffered from this syndrome.


Biogenic Amine Antidepressant Drug Lithium Salt Older Patient Anxiolytic Property 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Silverman C.: The Epidemiology of Depression. Baltimore, Johns Hopkins University Press, 1968.Google Scholar
  2. 2.
    Roth M: The natural history of mental disorders in old age. J Ment Sci 101: 281 - 301, 1955PubMedGoogle Scholar
  3. 3.
    Klein DF, Davis JM: Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, the Williams and Wilkins Company, 1969.Google Scholar
  4. 4.
    Bann TA: Psychopharmacology. Baltimore, the Williams and Wilkins Company, 1969.Google Scholar
  5. 5.
    Lifshitz K, Kline N: Psychopharmacology of the aged. In: Clinical Principles and Drugs in the Aging, (ed) JT Freeman, Springfield, Charles C Thomas, 1963.Google Scholar
  6. 6.
    Kral VA, Papetropoulos D: Treatment of geriatric patients. In: Psychopharmacology, (eds) NS Kline, HE Lehmann, Boston, Little, Brown, 1965.Google Scholar
  7. 7.
    Kuhn R: Über die Behandlung depressiver Zustände mit einem Iminodibenzylderivat (G-22355). Schweiz Med Wschr 87: 1135, 1957.PubMedGoogle Scholar
  8. 8.
    Goldberg LI: Monoamine oxidase inhibitors. JAMA 190: 456 - 462, 1964.CrossRefPubMedGoogle Scholar
  9. 9.
    Hollister LE et al: Evaluation of desipramine in depressive states. J New Drugs 3: 161 - 166, 1963.Google Scholar
  10. 10.
    Sterlin C et al: A comparative evaluation of doxepin and chlordiazepoxide in. the treatment of psychoneurotic outpatients. Curr Ther Res 12: 195 - 200, 1970.PubMedGoogle Scholar
  11. 11.
    Dovenmuehle RH: Psychiatry: Implementation. In: Clinical Features of the Older Patient, (ed) JT Freeman, Springfield, Charles C Thomas, 1965.Google Scholar
  12. 12.
    Barbeau A: L-DOPA therapy in Parkinson’s disease: A critical review of nine years’ experience. Canad Med Assoc J 101: 791, 1969.Google Scholar
  13. 13.
    Strang RR: Imipramine in treatment of parkinsonism, a double-blind placebo study. Brit Med J 2: 33 - 34, 1965.CrossRefPubMedGoogle Scholar
  14. 14.
    Laitinen L: Desipramine in treatment of parkinson’s disease. Acta Neurol Scandinav 45: 109 - 113, 1969.CrossRefGoogle Scholar
  15. 15.
    Hall CD, Weiss EA, Morris CE, Prange Ai: Rapid deterioration in patients with parkinsonism following tryptophan-pyridoxine administration. Neurol 22: 231 - 237, 1972.Google Scholar
  16. 16.
    Lidbrink P, Jonsson G, Fuxe K: The effect of imipramine-like drugs and antihistamine drugs on uptake mechanisms in the central noradrenaline and 5-hydroxytryptamine neurons. Neuropharmacol 10: 521 - 536, 1971.CrossRefGoogle Scholar
  17. 17.
    Pohlmeier H, Matussek N: Untersuchungen uber den Einfluss von Desmethyl Impramine = Pertofran auf den Parkinsonismus beim Menschen. Arch Psychiat Nervenkr 207: 175 - 185, 1965.CrossRefGoogle Scholar
  18. 18.
    El-Yousef MK, et al: Reversal by physostigmine of cogentin toxicity. Presented at the annual meeting of the American Psychiatric Association, Dallas, Texas, May 2, 1972.Google Scholar
  19. 19.
    Goldstein BJ, Pinosky DC: Clinical evaluation of doxepin in anxious depressed outpatients. Curr Ther Res 11: 169 - 177, 1969.PubMedGoogle Scholar
  20. 20.
    Ayd FJ: Recognizing and treating depressed patients. Mod Med, Nov 29, 1971, pp. 80 - 86.Google Scholar
  21. 21.
    Fann WE, et al: Doxepin: Effect on biogenic amine transport in man. Psychopharmacologia 22: 111 - 125, 1971.CrossRefPubMedGoogle Scholar
  22. 22.
    Schildkraut JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. American J Psychiat 122: 509 - 522, 1965.Google Scholar
  23. 23.
    Ayd FJ: Long-term administration of doxepin (Sinequan). Dis Nerv Sys 32: 617 - 622, 1971.Google Scholar
  24. 24.
    Abse DW, Dahlstrom WG: The value of chemotherapy in senile mental disturbances. JAMA 174: 2036 - 2042, 1960.Google Scholar
  25. 25.
    Hordern A, Holt NF, Burt CG, Gordon WF: Amitriptyline in depressive states: Phenomenology and prognostic considerations. Brit J Psychiat 109: 815 - 825, 1963.CrossRefPubMedGoogle Scholar
  26. 26.
    Sandifer MG, Wilson IC, Gambill JM: The influence of case selection and dosage in antidepressant drug trial. Brit J Psychiat 111: 142 - 148, 1965.CrossRefPubMedGoogle Scholar
  27. 27.
    Fink M, Klein DF, Kramer JC: Clinical efficacy of chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders. Psychopharmacologia 7: 27 - 36, 1965.CrossRefPubMedGoogle Scholar
  28. 28.
    Davis JM: Personal communication.Google Scholar
  29. 29.
    Prange AJ; The pharmacology and biochemistry of depression. Dis Nerv Sys 25: 217 - 221, 1964.Google Scholar
  30. 30.
    Bunney WE, Davis JM: Norepinephrine in depressive reactions. Arch Gen Psychiat 13: 483 - 494, 1965.CrossRefPubMedGoogle Scholar
  31. 31.
    Coppen A: The biochemistry of affective disorders. Brit J Psychiat 113: 1237 - 1264, 1967.CrossRefPubMedGoogle Scholar
  32. 32.
    Lapin IP, Oxenkrug GF: Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. The Lancet 1: 132 - 136, 1969.CrossRefGoogle Scholar
  33. 33.
    Glassman A: Indoleamines and affect disorders. Psychosom Med 31: 107 - 114, 1969.Google Scholar
  34. 34.
    Robison DS, et al: Aging, monamines, and monoamine-oxidase levels. The Lancet 1: 290 - 291, 1972.CrossRefGoogle Scholar
  35. 35.
    Perloff WH: Geriatric endocrinology. In: Clinical Features of the Older Patient, (ed) JT Freeman, Springfield, Charles C Thomas, 1965.Google Scholar
  36. 36.
    Busse EW, et al: Studies in the processes of aging. The strengths and weaknesses of psychic functioning in the aged. Amer J Psychiat 111: 896 - 901, 1955.PubMedGoogle Scholar
  37. 37.
    Goshorn RW: Psychiatry: Orientation. In: Clinical Features of the Older Patient, (ed) JT Freeman, Springfield, Charles C Thomas, 1965.Google Scholar
  38. 38.
    Winokur G, Cadoret R, Dorzab J, Baker M: Depressive disease: a genetic study. Arch Gen Psychiat 24: 135 - 144, 1971.CrossRefPubMedGoogle Scholar
  39. 39.
    Whybrow, PC, Mendels J: Toward a biology of depression: some suggestions from neurophysiology. Amer J Psychiat 125: 1491 - 1500, 1969.PubMedGoogle Scholar
  40. 40.
    Court JH: Manic-depressive psychosis: an alternative conceptual model. Brit J Psychiat 114: 1523 - 1530, 1968.CrossRefPubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1973

Authors and Affiliations

  • Arthur J. PrangeJr.

There are no affiliations available

Personalised recommendations